The BRAF mutation is associated with the prognosis in colorectal cancer
Background Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis. Objective We compared the KRAS and BRAF mutation status of CRC patients with their clinicopathological characteristics and exami...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2014-11, Vol.140 (11), p.1863-1871 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1871 |
|---|---|
| container_issue | 11 |
| container_start_page | 1863 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 140 |
| creator | Ahn, Tae Sung Jeong, Dongjun Son, Myoung Won Jung, Haeil Park, Soyoung Kim, Hyungjoo Bae, Sang Byung Kim, Han Jo Jeon, Young-Woo Lee, Moon Soo Baek, Moo-Jun |
| description | Background
Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis.
Objective
We compared the
KRAS
and
BRAF
mutation status of CRC patients with their clinicopathological characteristics and examined the effect of mutation status on survival rates.
Methods
DNA was extracted from 164 samples, and the mutation statuses of
KRAS
and
BRAF
were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate.
Results
Among the 164 CRC cases,
KRAS
mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan–Meier survival analysis,
KRAS
mutation was not significantly associated with survival (
p
= 0.971).
BRAF
mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of
BRAF
mutations was significantly decreased (
p
= 0.02).
Conclusions
The presence of
KRAS
mutation did not correlate with the various clinicopathological factors of CRC patients or the survival rate. However, the survival rate was reduced in
BRAF
-mutated CRC patients. Therefore,
BRAF
mutation could be an important prognostic factor in CRC patients. |
| doi_str_mv | 10.1007/s00432-014-1735-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1612290365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3459637621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-9ac261baef75a906de733aa614c0877b93df8c6839b1a5f2d48b7c5a3fe2ae2a3</originalsourceid><addsrcrecordid>eNp1kF1LwzAUhoMobk5_gDdS8Mabak4-mvZyDjeFgSDzOqRpunV0zUxaZP_elE4RQQiE5DznPYcHoWvA94CxePAYM0piDCwGQXl8OEFj6H-AUn6KxhgExJxAMkIX3m9xeHNBztGIsIwRStkYLVYbEz2-TefRrmtVW9kmqnykvLe6Uq0pos-q3URtgPbOrhvrQ7VqIm1r64xuVR1p1WjjLtFZqWpvro73BL3Pn1az53j5uniZTZexZoy0caY0SSBXphRcZTgpjKBUqQSYxqkQeUaLMtVJSrMcFC9JwdJcaK5oaYgKh07Q3ZAb1vnojG_lrvLa1LVqjO28hAQIyTBNeEBv_6Bb27kmbNdTOM0oAAkUDJR21ntnSrl31U65gwQse8tysCyDZdlblofQc3NM7vKdKX46vrUGgAyAD6Vmbdyv0f-mfgEpv4cO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1610893112</pqid></control><display><type>article</type><title>The BRAF mutation is associated with the prognosis in colorectal cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ahn, Tae Sung ; Jeong, Dongjun ; Son, Myoung Won ; Jung, Haeil ; Park, Soyoung ; Kim, Hyungjoo ; Bae, Sang Byung ; Kim, Han Jo ; Jeon, Young-Woo ; Lee, Moon Soo ; Baek, Moo-Jun</creator><creatorcontrib>Ahn, Tae Sung ; Jeong, Dongjun ; Son, Myoung Won ; Jung, Haeil ; Park, Soyoung ; Kim, Hyungjoo ; Bae, Sang Byung ; Kim, Han Jo ; Jeon, Young-Woo ; Lee, Moon Soo ; Baek, Moo-Jun</creatorcontrib><description>Background
Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis.
Objective
We compared the
KRAS
and
BRAF
mutation status of CRC patients with their clinicopathological characteristics and examined the effect of mutation status on survival rates.
Methods
DNA was extracted from 164 samples, and the mutation statuses of
KRAS
and
BRAF
were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate.
Results
Among the 164 CRC cases,
KRAS
mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan–Meier survival analysis,
KRAS
mutation was not significantly associated with survival (
p
= 0.971).
BRAF
mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of
BRAF
mutations was significantly decreased (
p
= 0.02).
Conclusions
The presence of
KRAS
mutation did not correlate with the various clinicopathological factors of CRC patients or the survival rate. However, the survival rate was reduced in
BRAF
-mutated CRC patients. Therefore,
BRAF
mutation could be an important prognostic factor in CRC patients.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-014-1735-y</identifier><identifier>PMID: 24942334</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Colorectal cancer ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - mortality ; Female ; Genetic Association Studies ; Genetic Predisposition to Disease ; Hematology ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Mutation, Missense ; Oncology ; Original Article – Cancer Research ; Prognosis ; Proportional Hazards Models ; Proteins ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins B-raf - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Tumorigenesis</subject><ispartof>Journal of cancer research and clinical oncology, 2014-11, Vol.140 (11), p.1863-1871</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-9ac261baef75a906de733aa614c0877b93df8c6839b1a5f2d48b7c5a3fe2ae2a3</citedby><cites>FETCH-LOGICAL-c442t-9ac261baef75a906de733aa614c0877b93df8c6839b1a5f2d48b7c5a3fe2ae2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-014-1735-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-014-1735-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24942334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahn, Tae Sung</creatorcontrib><creatorcontrib>Jeong, Dongjun</creatorcontrib><creatorcontrib>Son, Myoung Won</creatorcontrib><creatorcontrib>Jung, Haeil</creatorcontrib><creatorcontrib>Park, Soyoung</creatorcontrib><creatorcontrib>Kim, Hyungjoo</creatorcontrib><creatorcontrib>Bae, Sang Byung</creatorcontrib><creatorcontrib>Kim, Han Jo</creatorcontrib><creatorcontrib>Jeon, Young-Woo</creatorcontrib><creatorcontrib>Lee, Moon Soo</creatorcontrib><creatorcontrib>Baek, Moo-Jun</creatorcontrib><title>The BRAF mutation is associated with the prognosis in colorectal cancer</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Background
Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis.
Objective
We compared the
KRAS
and
BRAF
mutation status of CRC patients with their clinicopathological characteristics and examined the effect of mutation status on survival rates.
Methods
DNA was extracted from 164 samples, and the mutation statuses of
KRAS
and
BRAF
were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate.
Results
Among the 164 CRC cases,
KRAS
mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan–Meier survival analysis,
KRAS
mutation was not significantly associated with survival (
p
= 0.971).
BRAF
mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of
BRAF
mutations was significantly decreased (
p
= 0.02).
Conclusions
The presence of
KRAS
mutation did not correlate with the various clinicopathological factors of CRC patients or the survival rate. However, the survival rate was reduced in
BRAF
-mutated CRC patients. Therefore,
BRAF
mutation could be an important prognostic factor in CRC patients.</description><subject>Cancer Research</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Female</subject><subject>Genetic Association Studies</subject><subject>Genetic Predisposition to Disease</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Mutation, Missense</subject><subject>Oncology</subject><subject>Original Article – Cancer Research</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Tumorigenesis</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kF1LwzAUhoMobk5_gDdS8Mabak4-mvZyDjeFgSDzOqRpunV0zUxaZP_elE4RQQiE5DznPYcHoWvA94CxePAYM0piDCwGQXl8OEFj6H-AUn6KxhgExJxAMkIX3m9xeHNBztGIsIwRStkYLVYbEz2-TefRrmtVW9kmqnykvLe6Uq0pos-q3URtgPbOrhvrQ7VqIm1r64xuVR1p1WjjLtFZqWpvro73BL3Pn1az53j5uniZTZexZoy0caY0SSBXphRcZTgpjKBUqQSYxqkQeUaLMtVJSrMcFC9JwdJcaK5oaYgKh07Q3ZAb1vnojG_lrvLa1LVqjO28hAQIyTBNeEBv_6Bb27kmbNdTOM0oAAkUDJR21ntnSrl31U65gwQse8tysCyDZdlblofQc3NM7vKdKX46vrUGgAyAD6Vmbdyv0f-mfgEpv4cO</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Ahn, Tae Sung</creator><creator>Jeong, Dongjun</creator><creator>Son, Myoung Won</creator><creator>Jung, Haeil</creator><creator>Park, Soyoung</creator><creator>Kim, Hyungjoo</creator><creator>Bae, Sang Byung</creator><creator>Kim, Han Jo</creator><creator>Jeon, Young-Woo</creator><creator>Lee, Moon Soo</creator><creator>Baek, Moo-Jun</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>The BRAF mutation is associated with the prognosis in colorectal cancer</title><author>Ahn, Tae Sung ; Jeong, Dongjun ; Son, Myoung Won ; Jung, Haeil ; Park, Soyoung ; Kim, Hyungjoo ; Bae, Sang Byung ; Kim, Han Jo ; Jeon, Young-Woo ; Lee, Moon Soo ; Baek, Moo-Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-9ac261baef75a906de733aa614c0877b93df8c6839b1a5f2d48b7c5a3fe2ae2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Cancer Research</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Female</topic><topic>Genetic Association Studies</topic><topic>Genetic Predisposition to Disease</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Mutation, Missense</topic><topic>Oncology</topic><topic>Original Article – Cancer Research</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahn, Tae Sung</creatorcontrib><creatorcontrib>Jeong, Dongjun</creatorcontrib><creatorcontrib>Son, Myoung Won</creatorcontrib><creatorcontrib>Jung, Haeil</creatorcontrib><creatorcontrib>Park, Soyoung</creatorcontrib><creatorcontrib>Kim, Hyungjoo</creatorcontrib><creatorcontrib>Bae, Sang Byung</creatorcontrib><creatorcontrib>Kim, Han Jo</creatorcontrib><creatorcontrib>Jeon, Young-Woo</creatorcontrib><creatorcontrib>Lee, Moon Soo</creatorcontrib><creatorcontrib>Baek, Moo-Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahn, Tae Sung</au><au>Jeong, Dongjun</au><au>Son, Myoung Won</au><au>Jung, Haeil</au><au>Park, Soyoung</au><au>Kim, Hyungjoo</au><au>Bae, Sang Byung</au><au>Kim, Han Jo</au><au>Jeon, Young-Woo</au><au>Lee, Moon Soo</au><au>Baek, Moo-Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The BRAF mutation is associated with the prognosis in colorectal cancer</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>140</volume><issue>11</issue><spage>1863</spage><epage>1871</epage><pages>1863-1871</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Background
Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis.
Objective
We compared the
KRAS
and
BRAF
mutation status of CRC patients with their clinicopathological characteristics and examined the effect of mutation status on survival rates.
Methods
DNA was extracted from 164 samples, and the mutation statuses of
KRAS
and
BRAF
were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate.
Results
Among the 164 CRC cases,
KRAS
mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan–Meier survival analysis,
KRAS
mutation was not significantly associated with survival (
p
= 0.971).
BRAF
mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of
BRAF
mutations was significantly decreased (
p
= 0.02).
Conclusions
The presence of
KRAS
mutation did not correlate with the various clinicopathological factors of CRC patients or the survival rate. However, the survival rate was reduced in
BRAF
-mutated CRC patients. Therefore,
BRAF
mutation could be an important prognostic factor in CRC patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24942334</pmid><doi>10.1007/s00432-014-1735-y</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2014-11, Vol.140 (11), p.1863-1871 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1612290365 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Cancer Research Colorectal cancer Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Female Genetic Association Studies Genetic Predisposition to Disease Hematology Humans Internal Medicine Kaplan-Meier Estimate Male Medical prognosis Medicine Medicine & Public Health Middle Aged Mutation Mutation, Missense Oncology Original Article – Cancer Research Prognosis Proportional Hazards Models Proteins Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Tumorigenesis |
| title | The BRAF mutation is associated with the prognosis in colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T05%3A09%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20BRAF%20mutation%20is%20associated%20with%20the%20prognosis%20in%20colorectal%20cancer&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Ahn,%20Tae%20Sung&rft.date=2014-11-01&rft.volume=140&rft.issue=11&rft.spage=1863&rft.epage=1871&rft.pages=1863-1871&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-014-1735-y&rft_dat=%3Cproquest_cross%3E3459637621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1610893112&rft_id=info:pmid/24942334&rfr_iscdi=true |